Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Glukagonin kaltaisen peptidi-1 -reseptorin agonistit kohdistettuna multippeliskleroosiin (TAG-MS)

maanantai 9. marraskuuta 2026 päivittänyt: Johns Hopkins University

Glukagonin kaltaisen peptidi-1-reseptorin agonistien kohdentaminen MS-tautiin (TAG-MS): Vaiheen 2 satunnaistettu, kaksoissokko, rinnakkaishaarainen tutkimus

The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).

Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy).

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

120

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

  • Nimi: Study Manager
  • Puhelinnumero: 667-306-8153
  • Sähköposti: mvieira4@jh.edu

Opiskelupaikat

    • Kansas
      • Kansas City, Kansas, Yhdysvallat, 66103
        • Rekrytointi
        • University of Kansas Medical Center
        • Päätutkija:
          • Sharon Lynch, MD
        • Ottaa yhteyttä:
    • Maryland
      • Baltimore, Maryland, Yhdysvallat, 21287
        • Rekrytointi
        • Johns Hopkins University
        • Päätutkija:
          • Ellen Mowry, MD, MCR
        • Ottaa yhteyttä:
          • Margaret Vieira
          • Puhelinnumero: 667-306-8153
          • Sähköposti: mvieira4@jh.edu
    • New York
      • New York, New York, Yhdysvallat, 10029
        • Rekrytointi
        • Mount Sinai School of Medicine
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 60 vuotta (Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Diagnosis of MS (2024 criteria); clinically stable on MS therapy for ≥12 months without relapse or new lesions on brain MRI
  • Aged 18-60 years
  • Body mass index ≥27.0 kg/m2

Exclusion Criteria:

  • No GLP-1RA or GIP/GLP-1 RA in past year; no known hypersensitivity to medication class

  • No known Barrett's esophagus/gastroesophageal reflux disease, pancreatitis (including past), or gastroparesis

  • No personal/family history of medullary thyroid carcinoma or history of multiple endocrine neoplasia syndrome type 2

  • No chronic kidney disease (estimated glomerular filtration rate ≤50 mL/min) in past year, type 1 diabetes, known diabetic retinopathy, use of insulin or insulin-inducing medications*, dipeptidyl peptidase IV inhibitors**, or warfarin; current/active alcohol or illicit substance abuse

  • No concerns about candidacy of individual on part of person's neurologist or study team clinicians

  • Current or planned (next 2 years) pregnancy/breastfeeding; if able to become pregnant, agree to reliable contraception (contraception requirements as discussed below)***

    • currently-approved: Lispro, Aspart, Glulisine, Afrezza, Regular, Concentrated Regular, or Novolin, Velosulin, NPH, glargine, detemir, degludec, and premixed; approved secretagogues: sulphonylureas (e.g. glipizide (± metformin), glyburide (± metformin), glimepiride, pioglitazone/glimepiride) & meglitinide analogues (nateglinide and repaglinide); ** currently-approved:sitagliptin, saxagliptin, linagliptin, alogliptin ***Contraception: Participants of childbearing potential (participant has a uterus and is pre-menopausal) must agree to use contraception, using either one method with a failure rate of <1%/year, or two methods of lesser effectiveness:

Contraceptive methods with a failure rate of < 1% per year includes the following:

  • Combined (estrogen and progesterone containing) hormonal contraception (vaginal ring, birth control patch) or progesterone-only hormonal contraception (birth control injections, intrauterine device (IUD), or hormone-releasing implant), or copper IUD
  • Complete abstinence from sexual encounters with a person who has testes

Those who do not wish to use one of the above methods of contraception must use two methods. Options include:

  • Oral hormonal contraception plus one barrier method during sexual encounter with a person who has testes (below). While typically oral hormonal contraception has a low failure rate, it is possible that the absorption of contraceptive pills taken by mouth will be impacted by the study drug and thus lower contraceptive effectiveness. Thus, people using pills as primary contraception must, during asexual encounter with a person who has testes, use a second form of barrier contraceptive (below) or must change to one of the other contraceptive methods listed above.

  • Two forms of barrier contraception during sexual encounter with a person who has testes. Examples of barrier contraceptive methods include the following:

    • A condom with or without spermicide

    • A cap, diaphragm, or sponge with or without spermicide

      • Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Nelinkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Placebo Comparator: Plasebo

Placebo (saline solution)

Active Comparator: NLY01 (Study Drug)

5 mg subcutaneous weekly for the first 4 weeks, then 10 mg subcutaneous weekly, with pre-planned dose adjustments if adverse events prevent full dosage.

NLY01 is a pegylated exenatide

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in normalized (for head size) brain parenchymal volume (nBPV)
Aikaikkuna: Baseline, week 48, and week 96

Change in normalized (for head size) nBPV (mL). Measured from randomization to end of treatment (approximately 96 weeks). Presented as mean and standard deviation

Baseline, week 48, and week 96

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in normalized gray matter volume (mL)
Aikaikkuna: Baseline, week 48, and week 96

Presented as mean and standard deviation Measured from randomization to end of treatment (approximately 96 weeks).

Baseline, week 48, and week 96
Change in thalamic volume (mL)
Aikaikkuna: Baseline, week 48, and week 96

Measured from randomization to end of treatment (up to 96 weeks). Presented as mean and standard deviation.

Baseline, week 48, and week 96
Change in cortical thickness (mm)
Aikaikkuna: Baseline, week 48, and week 96

Measured from randomization to end of treatment (approximately 96 weeks), Presented as mean and standard deviation.

Baseline, week 48, and week 96
Change in retinal nerve fiber layer thickness
Aikaikkuna: Baseline, week 48, and week 96

Measured in μm, from randomization to end of treatment (approximately 96 weeks),

Baseline, week 48, and week 96
Change in ganglion cell/inner plexiform thickness
Aikaikkuna: Baseline, week 48, and week 96

Measured in μm, from randomization to end of treatment (approximately 96 weeks),

Baseline, week 48, and week 96
Disability progression as assessed by the Expanded Disability Status Scale (EDSS)
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

Expanded Disability Status Scale (EDSS). Scale range 0-10; higher score is worse disability progression

Approximately every 24 weeks, up to 96 weeks
Disability progression as assessed by the Multiple Sclerosis Functional Composite (MSFC)
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

The Multiple Sclerosis Functional Composite (MSFC) calculates a single Z-score from tests of ambulation, arm dexterity, and cognition. Scores are converted to a z score with a mean and standard deviation. A higher Z-score indicates better function.

Approximately every 24 weeks, up to 96 weeks
Disability progression as assessed by the Expanded Disability Status Scale-Plus
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

The EDSS-plus allows for documentation of progression as a composite value, considering progression as having occurred if any one of the following occurs: 20% increase in timed 25-foot walk or 9-hole peg test, or a 1.0-point increase in EDSS (if baseline is 5.5 or less) or a 0.5-point increase (if baseline is >5.5).

Approximately every 24 weeks, up to 96 weeks
Patient-reported disability progression as assessed by the Patient-Determined Disease Steps
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

Patient-Determined Disease Steps score range 0-8; higher is worse progression

Approximately every 24 weeks, up to 96 weeks
Change in self-reported anxiety as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported depression as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported fatigue as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported upper extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported lower extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported cognitive function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in positive affect/well-being as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported sleep disturbance as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported ability to participate in social roles Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported stigma as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale
Aikaikkuna: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Adverse events
Aikaikkuna: From randomization to week 96

Proportion of individuals in each arm experiencing adverse events

From randomization to week 96
Serious adverse events
Aikaikkuna: From randomization to week 96

Proportion of individuals in each arm experiencing serious adverse events

From randomization to week 96

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Ellen M Mowry, MD, MCR, Johns Hopkins University

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 28. huhtikuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Tiistai 1. tammikuuta 2030

Opintojen valmistuminen (Arvioitu)

Tiistai 1. tammikuuta 2030

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 11. maaliskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 24. maaliskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Perjantai 27. maaliskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 10. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 9. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • IRB00454859

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

De-identified individual participant data (IPD) that underlie the results reported in this publication, along with the protocol and analysis plan, will be available upon reasonable request to qualified researchers. Requests must include a proposal and are contingent on meeting regulatory approvals, including a signed data use agreement.

IPD-jaon aikakehys

Data will be available 6 months after publication and remain accessible for 12-24 months.

IPD-jaon käyttöoikeuskriteerit

Qualified researchers who have completed and signed approvals for data sharing.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .